title: Association of obesity and smoking with PSA and PSA velocity in men with prostate cancer.
abstract: Significant number of prostate tumors are slow growing and could probably be left untreated. However, many are aggressive and can spread rapidly causing patient suffering and/or death. Current technology does not allow physicians to differentiate between slow growing and aggressive tumors at diagnosis. Hence, many patients are exposed to invasive treatment and its associated morbidities such as incontinence and impotence. Markers that enable differentiation between slow and fast progressing cancer will allow physicians to prevent unnecessary treatments on men who may not need them, and focus on the men with aggressive disease. A longitudinal study was conducted (N = 140) using mixed effects regression models to determine the association of obesity and smoking toward prostate cancer progression. These models account for correlation because of repeated measures over time, thus, using maximum amount of information provided by the subject. Estimates thus obtained are more robust and reliable than those obtained using data from a single time point. Rate of change of prostate-specific antigen (PSA) over time (PSA velocity) was used as a measure of prostate cancer progression. Results indicate that PSA velocity of overweight and obese subjects (0.59 and 1.05 ng/mL/year) was not significantly different as compared with normal weight subjects (p values .91 and .31, respectively). For men in the highest tertile of pack-years of smoking, PSA velocity was significantly higher as compared with never smokers 1.57 ng/mL/year (p = .04). Further studies with larger sample sizes and study designs specific to above exposures are needed before recommendations can be made to reduce weight or reduce/quit smoking.
authors: Arizona Cancer Center, University of Arizona, Tucson, USA. algotar@email.arizona.edu
authors: Amit M
authors: AM
authors: Algotar
authors: Steven P
authors: SP
authors: Stratton
authors: James
authors: J
authors: Ranger-Moore
authors: M Suzanne
authors: MS
authors: Stratton
authors: C H
authors: CH
authors: Hsu
authors: Frederick R
authors: FR
authors: Ahmann
authors: Raymond B
authors: RB
authors: Nagle
authors: Patricia A
authors: PA
authors: Thompson
references: Epidemiol Rev. 2001;23(1):115-25
references: 11588835
references: J Natl Cancer Inst. 1997 Mar 5;89(5):385-9
references: 9060961
references: Cancer Epidemiol Biomarkers Prev. 1999 Apr;8(4 Pt 1):277-82
references: 10207628
references: Br J Cancer. 2003 Oct 6;89(7):1237-42
references: 14520453
references: Cancer. 2007 Feb 15;109(4):675-84
references: 17211863
references: Anticancer Drugs. 2003 Sep;14(8):595-600
references: 14501381
references: Eur Urol. 2008 Mar;53(3):468-77
references: 17997011
references: Cancer. 2005 Mar 1;103(5):1092-5
references: 15668913
references: Eur Urol. 2008 Mar;53(3):457-60
references: 18079050
references: Cancer. 2006 Jan 15;106(2):320-8
references: 16342294
references: JAMA. 2007 Nov 21;298(19):2275-80
references: 18029831
references: Am J Epidemiol. 2000 Mar 15;151(6):541-9
references: 10733035
references: Cancer Prev Res (Phila). 2010 Aug;3(8):1035-43
references: 20647337
references: Int J Cancer. 2007 Oct 1;121(7):1571-8
references: 17450530
references: Am J Ther. 2004 Nov-Dec;11(6):501-6
references: 15543092
references: Biometrics. 1982 Dec;38(4):963-74
references: 7168798
references: Nat Rev Cancer. 2004 Aug;4(8):579-91
references: 15286738
references: Cancer Causes Control. 1999 Aug;10(4):269-75
references: 10482485
references: J Natl Cancer Inst. 2003 Aug 20;95(16):1240-4
references: 12928350
references: CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108
references: 15761078
references: Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1977-83
references: 17035408
references: Cancer Epidemiol Biomarkers Prev. 2003 Jul;12(7):604-9
references: 12869398
references: Pathology. 2007 Dec;39(6):537-44
references: 18027255
references: Cancer Res. 1992 Jun 15;52(12):3323-8
references: 1375867
references: Eur Urol. 2007 Aug;52(2):331-43
references: 17507151
references: Eur Urol. 2005 Jan;47(1):16-21
references: 15582244
references: Acta Oncol. 2005;44(3):277-81
references: 16076700
references: Cancer. 2006 Mar 1;106(5):1047-53
references: 16456812
references: Cancer Epidemiol Biomarkers Prev. 2007 Jan;16(1):63-9
references: 17179486
references: Cancer. 2004 Nov 15;101(10 Suppl):2371-490
references: 15495199
references: Int J Cancer. 1997 Nov 27;73(5):634-8
references: 9398038